炎症性肠病临床试验的未来
本文综述了炎症性肠病(IBD)临床试验的演变,指出多种先进疗法的获批和靶向治疗策略的整合改变了疾病管理,关键随机对照试验规模与复杂性不断增加,但未来试验在成本、可行性和招募方面面临重大挑战,需采用创新方法提高早期和晚期试验效率。
要点
- 先进疗法获批和靶向治疗策略整合改变了IBD管理。
- 关键试验包括头对头生物制剂试验和先进联合治疗试验。
- 未来IBD试验面临成本、可行性和招募的重大挑战。
核心结论
- 过去几十年IBD药物治疗因多类先进疗法获批及更靶向治疗策略的整合而转变,未来试验需在成本、可行性和招募挑战下采用创新方法提高效率。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- 多项关键随机对照试验已完成或正在进行,包括首次头对头生物制剂试验、先进联合治疗试验、治疗策略与治疗目标试验及多个新药3期注册项目。
关键数值与推荐
- 未报告具体标准与数值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The medical management of inflammatory bowel disease (IBD) has been transformed over the past few decades by the approval of multiple classes of advanced therapies and the integration of more targeted treatment strategies for Crohn's disease and ulcerative colitis. These changes have been driven by an increasing number of pivotal randomized controlled trials, which have grown in size and complexity over time. Several landmark studies that are anticipated to change current IBD management paradigms have recently been completed or are on-going, including the first head-to-head biologic trials, advanced combination treatment trials, therapeutic strategy and treatment target trials, and multiple phase 3 registrational programs of novel compounds. Despite these advances, the future of IBD trials also faces major challenges with respect to cost, feasibility, and recruitment. Accordingly, innovative methods for early and late phase randomized controlled trials must be adopted. In this review, we provide a comprehensive overview of the evolution of modern IBD trials, discuss methods for improving trial efficiency in early and late phase development, and provide insights into the interpretation and implications of these data for clinical care.
引用
- Ma C, Solitano V, Danese S, et al. The Future of Clinical Trials in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2024. PMID: 39025252. doi:10.1016/j.cgh.2024.06.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。